Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16424112 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1POLBHPGD | |
| SCHEMBL16424100 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1POLBHPGD | |
| SCHEMBL16433812 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1POLBHPGD | |
| SCHEMBL16423599 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1POLBHPGD | |
| SCHEMBL16433761 | 0.81 | TSHR (0.49) | SMN1; SMN2ALDH1A1POLBHPGD | |
| SCHEMBL16424043 | 0.81 | TSHR (0.49) | SMN1; SMN2ALDH1A1POLBHPGD | |
| SCHEMBL16433815 | 0.81 | TSHR (0.49) | SMN1; SMN2ALDH1A1POLBHPGD | |
| SCHEMBL6900694 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1POLBHPGDHTT | |
| SCHEMBL2965074 | 0.76 | CHRM2 (0.52) | — | |
| SCHEMBL8226507 | 0.76 | CHRM2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027587-B1 | 1,2-DISUBSTITUTED CYCLOBUTYL COMPOUNDS | ESTEVE LABOR DR (ES) | 2018-07-25 | — | — | EP | disclosed |
| EP-3027587-B1 | 1,2-DISUBSTITUTED CYCLOBUTYL COMPOUNDS | ESTEVE LABOR DR (ES) | 2018-07-25 | — | — | EP | disclosed |
| US-9464069-B2 | 1,2-disubstituted cyclobutyl compounds | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-10-11 | — | — | US | disclosed |
| US-9464069-B2 | 1,2-disubstituted cyclobutyl compounds | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-10-11 | — | — | US | disclosed |
| US-9464069-B2 | 1,2-disubstituted cyclobutyl compounds | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-10-11 | — | — | US | disclosed |
| US-20160185755-A1 | 1,2-DISUBSTITUTED CYCLOBUTYL COMPOUNDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-06-30 | — | — | US | disclosed |
| US-20160185755-A1 | 1,2-DISUBSTITUTED CYCLOBUTYL COMPOUNDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-06-30 | — | — | US | disclosed |
| US-20160185755-A1 | 1,2-DISUBSTITUTED CYCLOBUTYL COMPOUNDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-06-30 | — | — | US | disclosed |
| EP-3027587-A1 | 1,2-DISUBSTITUTED CYCLOBUTYL COMPOUNDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015014816-A1 | 1,2-DISUBSTITUTED CYCLOBUTYL COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015014816-A1 | 1,2-DISUBSTITUTED CYCLOBUTYL COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-02-05 | — | — | WO | disclosed |
| EP-2832720-A1 | 1,2-disubstituted cyclobutyl compounds | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2015-02-04 | — | — | EP | disclosed |
| EP-2832720-A1 | 1,2-disubstituted cyclobutyl compounds | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2015-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185755-A1 | 1,2-DISUBSTITUTED CYCLOBUTYL COMPOUNDS | OPRL1, OPRK1, PTGS1 | SMN1; SMN2 1243/4885ALDH1A1 449/4885NPC1 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.